Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.54 |
| ▸ | AR | P10275 | 7/20 | 0.51 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.46 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 2/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | RORC | P51449 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | ALB | P02768 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | GHSR | Q92847 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20187001 | 0.89 | SLC22A12 (0.55) | SLC22A12ARIMPDH2PGRCNR2 | |
| SCHEMBL20186971 | 0.88 | SLC22A12 (0.54) | SLC22A12ARIMPDH2PGRFFAR4 | |
| SCHEMBL20186995 | 0.88 | SLC22A12 (0.54) | SLC22A12ARPLA2G7IMPDH2PGR | |
| SCHEMBL20186990 | 0.84 | RORC (0.51) | SLC22A12ARPLA2G7FFAR4CNR2 | |
| SCHEMBL20186964 | 0.84 | IMPDH2 (0.50) | SLC22A12ARIMPDH2PGRRORC | |
| SCHEMBL20187005 | 0.81 | SLC22A12 (0.54) | SLC22A12PLA2G7IMPDH2 | |
| SCHEMBL20186979 | 0.81 | IMPDH2 (0.48) | SLC22A12IMPDH2PGRRORC | |
| SCHEMBL20186969 | 0.81 | IMPDH2 (0.48) | SLC22A12IMPDH2PGRRORC | |
| SCHEMBL20186961 | 0.81 | FFAR4 (0.67) | ARFFAR4RORC | |
| SCHEMBL20186965 | 0.81 | RORC (0.48) | SLC22A12IMPDH2PGRRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10905120-B2 | ABA receptor agonists that modulate transpiration | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-02-02 | — | — | US | disclosed |
| US-20180146666-A1 | ABA RECEPTOR AGONISTS THAT MODULATE TRANSPIRATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10905120-B2 | ABA receptor agonists that modulate transpiration | ADORA2A, ADORA1, AAK1 | SLC22A12 930/4885AR 1334/4885PLA2G7 1724/4885 |
| US-20180146666-A1 | ABA RECEPTOR AGONISTS THAT MODULATE TRANSPIRATION | ADORA2A, ADORA1, AAK1 | SLC22A12 930/4885AR 1334/4885PLA2G7 1724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.